© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Mesna’s journey in medicine began in Germany in the late 1970s. Researchers searched for a way to protect patients from the harsh side effects of chemotherapy drugs like ifosfamide and cyclophosphamide. Bladder toxicity showed up in too many cases, leaving patients with more than just the struggle against cancer. Scientists zeroed in on sulfhydryl compounds, hoping to neutralize these toxic metabolites. After early experiments and patient trials, mesna, or sodium 2-mercaptoethane sulfonate, emerged as a frontline defense. Regulatory bodies gave it approval across Europe, then Asia, and finally, the US Food and Drug Administration recognized its value. Hospital pharmacies integrated mesna as a routine safeguard during certain chemotherapy regimens, and its value moved from research journals into real hospital practice—a rare success story of translating bench science to bedside utility.
Mesna comes formulated in aqueous solutions, usually as either injectable or oral agents—though the injectable version dominates most clinical settings. It goes straight into IV bags or syringes, ready to infuse alongside cytotoxic drugs. Pharmacies often store mesna in amber glass containers to preserve its integrity. The compound itself offers a sharp, sulfurous odor and a bitter taste, though only medical staff ever gets close to pure mesna. Hospitals rely on FDA-labeled concentrations, with storage in tightly controlled temperature and humidity because even minor fluctuations can degrade the thiol group that gives mesna its protective punch. Pharmacies keep strict inventory, pairing mesna’s administration protocol with each dosing round of ifosfamide or cyclophosphamide, ensuring the uroprotectant is always on hand for high-risk regimens.
Mesna’s molecular formula is C2H5NaO3S2, and its molecular weight clocks in at 164.2 g/mol. It shows up as a white, crystalline powder, though clinical practitioners only see it dissolved in sterile water. Mesna is highly soluble in water, with almost no solubility in organic solvents like ethanol or ether. The compound carries a free thiol (–SH) group, which gives it powerful nucleophilic characteristics—this same group underpins its toxicity-quenching mechanism in the urinary tract. Its melting point sits around 134–136°C, but in the injectable form, hydrolysis and oxidation pose greater storage risks than temperature fluctuation. The pKa of the thiol group helps regulate its reactivity, and in vivo, mesna rapidly undergoes reversible oxidation to its disulfide, dimesna. Scent alone can reveal its chemistry—mesna smells like burnt matches, warning lab workers of its sulfur content even before lab tests confirm identification.
Vials typically contain mesna at concentrations of 100 mg/mL or 200 mg/mL, sterile and pyrogen-free. Each vial’s label documents batch number, expiration date, precise volume, and the full list of excipients—usually sterile water or saline. Safety instructions appear prominently, reminding pharmacy staff to avoid exposure to ambient air for prolonged periods. Manufacturers comply with FDA or EMA requirements on clear typeface and color coding, which helps clinicians avoid mix-ups with other sulfhydryl medications. The package insert explains detailed administration schedules linked to ifosfamide or cyclophosphamide dosing, including recommended dilution, appropriate IV lines, and compatibility with other drugs. Licensing authorities make sure that each batch conforms to strict purity specs—levels of free thiol, residual solvents, endotoxin, and pH fall within narrow bands, backed by batch release certificates accessible for institutional recordkeeping.
Synthesis of mesna involves ethylene sulfonic acid and sodium thiosulfate, reacting in aqueous solution under carefully controlled temperature and pH. Reaction starts with sodium 2-chloroethane sulfonate, which undergoes nucleophilic substitution with sodium hydrogen sulfide, swapping the chlorine atom for a sulfhydryl group. The final product gets crystallized from water, then further purified by recrystallization, usually in an industrial-scale batch reactor. Quality control kicks in at each step—chemical analysts check for unreacted feedstock, test for heavy metal contamination, and verify the integrity of the thiol group by iodometric titration or high-performance liquid chromatography. Final product moves to sterile filling lines, undergoing terminal sterilization before packaging and shipment. Consistency in process prevents degradation, guaranteeing hospital staff receive the same reliable uroprotectant from batch to batch.
The chemistry shaping mesna’s impact stems from its reactive thiol group. Inside the body, mesna’s –SH group attacks and neutralizes acrolein and other unsaturated aldehyde metabolites produced during the metabolism of certain chemotherapy drugs. This scavenging activity converts mesna into its disulfide dimer, dimesna, which remains inactive until the kidneys, where reduction regenerates the free thiol and continues the protection. Chemists interested in modifying mesna have explored analogs with altered side chains or modified sulfonate moieties, hoping to tweak absorption or half-life, but most attempts sacrifice the activity or safety profile that makes the parent molecule useful. Mesna itself doesn’t undergo significant metabolic breakdown except via reversible oxidation, which lets it cycle between active and inactive forms throughout the excretory process. Incompatibility with platinum drugs or oxidizing agents requires careful attention during co-administration, as unwanted side reactions can rob mesna of its protective value.
Clinicians, pharmacists, and researchers all encounter mesna under a range of formal and informal names. Chemically, it's sodium 2-mercaptoethane sulfonate or sodium 2-sulfanylethanesulfonate. Pharmaceutical vendors market it as Uromitexan in Europe, Mesnex in the United States, and under several generic designations globally. The World Health Organization assigns the International Nonproprietary Name (INN) “mesna,” which most journals and drug formularies adopt. Hospital inventory systems and insurance codes mark every vial, whether generic or branded, making sure ordering errors remain rare even when multiple suppliers ship product.
Administering mesna safely means more than following pharmacy procedure. Health care workers train to avoid needle sticks and vapor exposure, since even though mesna itself rarely causes skin irritation, any interaction with chemotherapy residue amplifies risk. Gloves and gowns form the first line of defense. Regulatory agencies set tight rules for shelf life, storage, and waste disposal—mesna waste, although less hazardous than cytotoxic agents, still demands segregation from regular trash and processing in certified medical waste incinerators. Pharmacovigilance teams log each adverse event, tracking rashes, rare allergic reactions, or accidental overdoses—though with mesna, serious adverse outcomes stay few and far between compared to the severity of the chemotherapy it supports.
Mesna’s claim to fame lives in oncology. Hospitals link its use to regimens involving ifosfamide, cyclophosphamide, and, more rarely, other nitrogen mustards. Physicians order mesna for cancers that require high-dose alkylating agents: lymphomas, sarcomas, and certain leukemias. Outside oncology, occasional nephrologists borrow mesna for supporting kidney patients where exposure to toxic thiols threatens the urinary tract, but that remains off-label. Pediatric oncologists, in particular, depend on mesna during protocols for rhabdomyosarcomas or high-risk leukemias, where children would otherwise face severe bladder complications. Clinical pharmacists advocate for mesna during roundtable reviews, using it as leverage against hospitals cutting costs, because the cost of treating hemorrhagic cystitis dwarfs the outlay for mesna vials.
Pharmaceutical scientists continue to investigate ways to extend mesna’s role. Ongoing studies test alternative dosing forms, like slow-release oral preparations or extended-infusion formulations, aimed at further minimizing adverse bladder effects. Molecular chemists work on derivatives with longer circulation times, though direct clinical benefit over standard mesna remains elusive. Translational studies pivot toward understanding whether mesna’s antioxidant properties might work in preventing chemotherapy-related toxicity in other organs, like the heart or nervous system. Some early-phase research asks if mesna could neutralize toxic metabolites from environmental exposures—zeroing in on industrial chemicals or agricultural runoff that share structural similarities with acrolein. In every case, trials measure whether efficacy, safety, and cost offer a real net benefit for patients, and so far, the parent molecule keeps holding its ground as the gold standard uroprotectant.
Mesna itself, unlike the chemotherapy drugs it defends against, presents a remarkably low toxicity profile. Animal studies exposed rats and rabbits to escalating doses, finding that mesna’s main risk lies in transient gastrointestinal upset or, at worst, rare hypersensitivity reactions. Its route through the body avoids significant hepatic metabolism, so liver risks stay low, and kidneys swiftly excrete both mesna and its inactive disulfide. In people, reported side effects include mild rash, bad taste, rare anaphylaxis, and at very high doses, nausea or vomiting. Toxicologists track these reactions closely, hoping to understand whether repeated courses in chemotherapy cycles build up overlooked long-term risks. To date, evidence argues that mesna offers a degree of bladder protection unmatched by other agents, with little trade-off in systemic safety, making it a quietly reliable tool on the oncology ward.
As cancer care evolves toward new molecular therapies, the need for alkylating agents hasn’t faded overnight. Researchers look ahead, evaluating whether combining mesna with contemporary drug delivery systems or nanomedicines might improve both protection and patient experience. Precision dosing software hints at customizing mesna schedules based on individual genetics, tailoring protection without waste. The pharmaceutical industry eyes bioequivalent generics and more efficient synthesis methods, aiming to drive costs down for hospitals. Public health advocates point out that increased access to mesna in low- and middle-income countries could boost chemotherapy safety, reducing avoidable suffering. Even as immunotherapy and targeted oncology drugs gather headlines, for families and caregivers facing high-dose chemotherapy, mesna keeps a critical role—shielding patients from a life-changing complication that, left unchecked, could overshadow any victory against cancer itself.
Anyone who’s sat at the bedside of a loved one getting chemotherapy knows the treatments don’t pull their punches. Chemotherapy can target more than just cancer cells. It can hit healthy tissues, too. One drug that often comes into play during some of these tougher treatments is mesna.
Mesna’s story fits squarely into the day-to-day battles of cancer care. Some chemotherapies, especially ifosfamide and cyclophosphamide, can protect lives but also raise the risk of bladder damage. That means blood in the urine, pain, and even long-term complications. Doctors started giving mesna to neutralize the toxic byproducts in the bladder, letting the real cancer-fighting drugs do their job with less collateral damage.
The fact that treatments as aggressive as chemotherapy exist speaks to the seriousness of the disease. No one takes these drugs just for a cold. Oncologists, patients, and families accept a certain level of risk because the alternative often looks worse. Every tool that helps soften that risk matters. Mesna lets doctors use very effective medications without exposing patients to the worst of their side effects.
Let’s break it down: Certain chemotherapy drugs break apart in the body and leave bits behind that don’t just float around harmlessly. Acrolein is the main offender. It’s harsh enough to burn the inside of the bladder. Mesna acts almost like a sponge, soaking up acrolein so it never gets a chance to do irreversible harm. The result? A lower risk of hemorrhagic cystitis—a fancy term for a deeply uncomfortable and dangerous inflammation in the bladder.
I’ve seen mesna at work in real hospital settings. Nurses keep close track of hydration, making sure patients get enough fluids while on these chemotherapy protocols. Mesna’s usually given right before, at the same time, and after the chemo infusion. There’s less fear that an aggressive treatment will get cut short just because of bladder toxicity. Watching people finish their prescribed cycles without long bathroom visits reminds everyone—staff and patients—that little scientific victories count for something big.
Hospitals give mesna thousands of times every year across the U.S. Reports from the American Cancer Society show ifosfamide and cyclophosphamide continue in common use, so mesna remains a daily presence in oncology units. Without it, the rates of urinary tract complications would take a step back to earlier decades when chemo patients faced pain and bleeding as normal side effects.
Cancer care moves forward inch by inch. Mesna stands out as one of those practical fixes that brings modern medicine closer to its promise. The best approach looks for smart ways to keep cancer treatment effective without calling for unnecessary suffering on the side. Medicine benefits from a sharp focus on reducing harm. That’s not just about comfort—it’s about helping more people get the full treatment and a fair shot at a cure.
Mesna isn’t a cure for cancer. Still, it proves something about the value of listening to patients: Teams can turn up simple tools to solve big problems. With every year that passes, the knowledge behind these drugs gets stronger. People battling cancer and those standing by them deserve that progress, detail by detail.
Chemotherapy comes with a long list of possible side effects, and for many people, the threat of bladder damage from certain drugs can feel overwhelming. Cyclophosphamide and ifosfamide, both used to treat cancer, don’t stop working once they’ve done their job against cancer cells. The way these drugs break down in the body creates toxic compounds like acrolein. That’s where Mesna steps in. Understanding how this medicine works makes all the difference if you or someone you care about faces this part of treatment.
Hospitals rely on Mesna because it does a specific job: it patrols the bladder, neutralizing the byproducts from chemotherapy that can cause bleeding and irritation. Acrolein, the main culprit, travels through the body and passes through the urinary tract, burning and scarring the bladder lining if left unchecked. Mesna, which stands for mercaptoethane sulfonate sodium, hunts down and binds with acrolein in the urine, changing it chemically so it can’t hurt the bladder.
It’s important to ask medical teams about the risk of hemorrhagic cystitis, which is the medical name for bladder bleeding linked to chemotherapy drugs. In my experience, patients fear this side effect as much as any other complications. It’s hard to see red in the toilet bowl and not panic, and it’s just as hard for doctors to hear about persistent pelvic pain or see damage resulting from these treatments. Mesna helps keep those conversations shorter and calmer, which makes a real difference to both patient and provider.
Mesna isn’t complicated to give. Usually, it’s delivered through an IV at the same time as chemotherapy, or it’s handed out as a pill right after. Medical teams match the Mesna dose to the amount of chemotherapy drug given and adjust the schedule to follow urine output and kidney function. Most pharmacies keep it on hand because doctors know that any patient on ifosfamide or high doses of cyclophosphamide could need protection at a moment’s notice.
The science checks out. Decades of studies—including large trials and long-term follow-up projects—show that rates of bladder irritation and bleeding drop dramatically if Mesna is used. The evidence spans across continents, age groups, and cancer types. In terms of safety, Mesna’s track record holds up. Side effects remain rare, usually limited to mild reactions like headache or rash, and none match the risk that acrolein poses.
Families go through enough stress during cancer care. Mesna changes the experience, helping patients finish chemotherapy cycles without added pain or complications. On the ground, giving people access to Mesna is a matter of education and logistics. In resource-limited hospitals, gaps in supply cost lives. Even in bigger centers, dosing schedules can be mixed up if communication falters. Pharmacists, nurses, and doctors benefit from regular training that keeps them sharp on Mesna schedules.
Patients and caregivers should speak up about bladder symptoms and ask about Mesna if facing drugs like ifosfamide or cyclophosphamide. For me, being able to explain to a worried parent exactly what Mesna does—and reassure them with facts—feels like giving back some control in a situation that often feels unpredictable. Throwing the right tools at the right time can tip the scale toward healing rather than harm.
Mesna steps in as a protector for people getting certain chemotherapy drugs, especially ifosfamide or cyclophosphamide. These heavy-duty treatments can damage the bladder, causing serious irritation or bleeding. Mesna’s job is to bind with the harmful byproducts so they don’t harm the body. Speaking as someone who’s seen friends go through chemotherapy, I know how grateful they’ve been for any drug that offers relief from harsh side effects. At the same time, every medication brings its own risks. Mesna is no exception.
People using Mesna often mention mild problems like nausea, vomiting, diarrhea, or headache. Some get a strange taste in their mouths soon after the drug goes in. Others might notice their stomach feels upset or that they feel tired for a few hours afterward. These issues rarely surprise anyone who’s fought through cancer treatment, but they can make an already hard journey tougher.
A rash or redness can show up where nurses give the injection. Dry mouth and limb pain are also near the top of the list. While these symptoms don’t usually force someone to stop the medication, they definitely cause frustration. Imagine going through weeks of treatment where every day brings a slight new irritation or discomfort.
Rare but real risks come with using Mesna. Some people break out in hives or have swelling around their face—classic signs of an allergic reaction. This can lead to difficulty breathing, which is dangerous if it doesn’t get medical attention right away. There have been reports of severe skin reactions, which can threaten lives if left untreated.
In a few cases, people taking Mesna report blood in their urine or unexplained fever. While the medicine’s main job is to prevent bladder harm, it is possible—even though it works well most of the time—for bladder or urinary problems to appear. Staying alert for back pain, burning while peeing, or pink urine pays off big time. I remember a neighbor’s story: swift reporting of these symptoms got her doctors to adjust her care in time.
Some research also points to low blood counts in rare cases. People may notice easy bruising, nosebleeds, or just feeling wiped out. Checking blood work during treatment tells the full story. That is why routine lab checks are part of every cancer center’s protocol.
Drinking extra fluids can help flush any lingering chemicals and soothe the bladder. Doctors usually recommend staying well hydrated long before the symptoms appear. Sometimes, splitting the total dose of Mesna across several smaller doses reduces nausea. Nurses keep a close eye for any skin changes or swelling at the injection site.
Open communication matters. I’ve found that patients who speak up about new or strange symptoms get better support. Every body reacts differently—no one should feel they’re overreacting by telling their care team about a rash or digestive problem. In my experience, small updates can turn into big changes in care, making the overall experience less stressful and more manageable.
Mesna saves lives and keeps people safer during chemo, but folks deserve to know what they’re facing. Being informed doesn’t just let patients react quickly. It gives them back a little control in a process that often feels overwhelming. Close monitoring, honest dialogue, and support from health care teams go a long way to keep Mesna’s side effects in check. No one wants to trade one problem for another—knowledge makes all the difference.
Mesna is a medicine built to protect the bladder during treatments that use certain chemotherapy drugs, such as cyclophosphamide or ifosfamide. These powerful drugs save lives but put the bladder lining at risk. The mind sometimes drifts to those hospital rooms filled with pale faces and tough conversations, but behind it all is a constant drive to prevent side effects that can haunt patients long after their chemo drips end.
Folks working in oncology clinics often choose between giving Mesna through a vein or as a pill. IV Mesna acts quickly, which helps when patients receive high doses of bladder-irritating chemotherapy. The nurse attaches a bag of clear fluid to the patient’s IV pole, and Mesna travels right into the bloodstream. This route works well for those who struggle to swallow medicines, as well as those experiencing nausea or vomiting from chemotherapy.
Sometimes, Mesna pills do the trick—especially if someone is not hooked up to an IV all the time. People swallow the tablet with water, often on a strict schedule set by their care team. The biggest challenge with oral Mesna is making sure every dose really gets into the system. Vomiting or poor absorption can leave the bladder unprotected. Doctors and pharmacists watch for these issues closely. If there’s any doubt, they switch to the IV kind for steady results.
Protecting the bladder isn’t about just giving a single shot. Mesna dosing follows a careful schedule, often spaced around the chemotherapy drug. For example, chemotherapy might run first, with Mesna given at the same time, then repeated at set intervals a few hours apart—like a safety net that catches potential toxins before they cause bleeding or damage. Many clinicians double and triple-check dose timing, since missing a window can put someone at risk for hematuria, which can show up as blood in the urine or pain on urination.
I’ve heard stories in cancer wards where patients, tired from treatment, sometimes sleep through alarms or forget a dose. Oncology nurses make sure reminders are clear and that everyone knows the importance of staying on track. It’s not just about following rules—it’s about keeping a dangerous side effect from derailing recovery.
Chemotherapy regimens run on precision, and Mesna fits right into that philosophy. Exact doses get calculated based on the chemotherapeutic agent, its dose, and patient weight or surface area. Under-dosing means less protection. Overdosing brings its own set of complications, from headaches to allergic reactions. Teams always talk through any kidney or liver concerns, since these organs handle how fast Mesna moves in and out of the body. In some clinics, pharmacists join rounds to check calculations and talk about any signs of interaction with other drugs.
Quality of care means more than just surviving treatment. Avoiding side effects like bladder irritation saves people stress, pain, and sometimes extra days in the hospital. Every oncology professional has stories of patients who felt strong enough to walk or laugh with loved ones, simply because their side effects stayed controlled. Mesna, given thoughtfully, plays a quiet but crucial role in making those days possible.
Delivering Mesna has never been about a one-size-fits-all recipe. Whether given by IV or by mouth, the process always centers around the patient’s needs and the risks posed by their treatment. Messages on hospital chartboards remind everyone of the next dose. Family members sometimes ask how the medicine works, wanting to do their part in making sure nothing falls through the cracks.
Healthcare workers watch for the small details—the right timing, the right dose, honest conversations about how a patient is feeling. That’s where real safety and comfort come in. As cancer therapies grow ever more complex, support drugs like Mesna deserve just as much attention to detail and care as the main treatments themselves.
Mesna steps in as a kind of bodyguard during certain chemotherapy treatments. Doctors prescribe it to shield the bladder from the harsh effects of drugs like ifosfamide and cyclophosphamide. These drugs can damage the lining of the urinary tract, and Mesna binds to the toxic byproducts, making them safer for your body to handle. Over the years, pharmacists and nurses have gotten pretty good at weaving Mesna into treatment schedules alongside other strong medications.
Like any other drug, Mesna doesn’t work in a vacuum. The issue of mixing medications comes up a lot among patients who already juggle pills for high blood pressure, diabetes, or even something as simple as a runny nose. Plenty of people look at their basket of pills and wonder which combinations play nicely, and which ones risk causing a problem nobody needs during cancer care.
Looking at published studies and guidance from sources like the FDA, Mesna actually shows a low risk for sparking big drug interactions. It usually floats in and out of the system quickly, and doesn’t clog up the liver’s usual pathways for breaking down medicines. That takes a big worry off the table. Most folks can take Mesna without having to toss out other important prescriptions like painkillers, antibiotics, or blood pressure pills.
A few caution flags still go up for some folks. Mesna’s main trick is making urine less harmful, so it pulls a lot of water through the kidneys. Mix it with other drugs that also drain water — like diuretics, which help get rid of extra fluid — and the push may be too much for someone whose kidneys already struggle. Chemotherapy can stress kidneys, and adding extra traffic sometimes tips the balance.
Another area to watch comes from sulfur. Mesna contains a sulfur group, a detail that rarely matters but might for anyone with severe allergies to sulfa drugs. While Mesna isn’t the same as antibiotics like sulfamethoxazole, it’s worth mentioning allergies to nurses and doctors.
Drugs that shift urine’s acidity can mess with Mesna’s work, too. Certain antacids or treatments for gout can sometimes tweak urine’s pH, which leads to less Mesna in the bladder where it’s needed most. Pharmacists usually check for this when reviewing a patient’s list.
Nobody expects every cancer patient to remember the fine print on every drug, but speaking up about every medication — and every supplement, cough syrup, or over-the-counter remedy — can make a difference. Sometimes people skip telling their cancer team about herbal products or even basic pain relievers, not realizing those can create problems the team doesn’t expect.
For caregivers and patients, the best tool is an updated medication list. Pharmacies and hospitals often use medication reconciliation to make sure combinations don’t cause headaches down the line, both literally and figuratively. The more details the team has, the safer everyone feels.
While Mesna rarely shows its rough side in drug interactions, there’s never room for taking things lightly. New therapies and unusual drugs pop up all the time, and every patient’s metabolism handles medicine in a slightly different way. Pharmacy teams often lead the charge here, keeping up-to-date with the shifting landscape and adjusting medications when needed.
Talking with your doctor or pharmacist about all drugs, sticking with medical advice, and showing up for lab work can cut down on surprises. More studies down the road may reveal rare interactions that never popped up before, especially as cancer treatments grow more complex. Trusting open communication and expert review helps patients get the best care, with Mesna doing its job quietly in the background.
| Names | |
| Preferred IUPAC name | sodium 2-sulfanylethanesulfonate |
| Other names |
Uromitexan Sodium 2-mercaptoethane sulfonate |
| Pronunciation | /ˈmɛz.nə/ |
| Identifiers | |
| CAS Number | 19767-45-4 |
| 3D model (JSmol) | `3D model (JSmol)` string for **Mesna**: ``` CCS(=O)CCS(=O)C ``` This is the SMILES (Simplified Molecular Input Line Entry System) string of Mesna, which can be used in JSmol or other chemical visualization tools to generate its 3D model. |
| Beilstein Reference | 3920899 |
| ChEBI | CHEBI:6916 |
| ChEMBL | CHEMBL1205 |
| ChemSpider | 2257 |
| DrugBank | DB06744 |
| ECHA InfoCard | 100.064.919 |
| EC Number | 3.4.4.2 |
| Gmelin Reference | 61314 |
| KEGG | C07344 |
| MeSH | D008776 |
| PubChem CID | 3878 |
| RTECS number | KV0299000 |
| UNII | 08ZQ2R6ZG8 |
| UN number | UN2810 |
| Properties | |
| Chemical formula | C2H5NaO2S2 |
| Molar mass | 164.18 g/mol |
| Appearance | Clear, colorless to light yellow aqueous solution |
| Odor | Odorless |
| Density | 0.414 g/cm³ |
| Solubility in water | Freely soluble |
| log P | -2.06 |
| Acidity (pKa) | 2.0 |
| Basicity (pKb) | 8.20 |
| Magnetic susceptibility (χ) | -65.0e-6 cm³/mol |
| Refractive index (nD) | 1.340 |
| Viscosity | Low viscosity |
| Dipole moment | 3.05 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 247.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -372.6 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -2065 kJ/mol |
| Pharmacology | |
| ATC code | V03AF01 |
| Hazards | |
| Main hazards | May cause respiratory irritation. Causes serious eye irritation. Causes skin irritation. |
| GHS labelling | GHS labelling: Danger. Hazard statements: H302, H315, H319, H335. Precautionary statements: P261, P305+P351+P338, P337+P313. |
| Pictograms | productCard.pictograms.PRESCRIPTION,productCard.pictograms.HOSPITAL,productCard.pictograms.INJECTION |
| Signal word | Warning |
| Hazard statements | Hazard statements: "H302, H332, H319 |
| Precautionary statements | P201, P202, P261, P264, P270, P272, P280, P302+P352, P304+P340, P305+P351+P338, P308+P313, P321, P332+P313, P333+P313, P337+P313, P362+P364, P405, P501 |
| NFPA 704 (fire diamond) | 1-1-0 |
| Lethal dose or concentration | LD50 (mouse, intravenous): 2.6 g/kg |
| LD50 (median dose) | LD50 (median dose): 2300 mg/kg (rat, intravenous) |
| NIOSH | N99 |
| PEL (Permissible) | PEL (Permissible exposure limit) for Mesna has not been established. |
| REL (Recommended) | 600 mg |
| Related compounds | |
| Related compounds |
Dimesna Ifosfamide Cyclophosphamide |
